U.S. Software Stock News

Recent performance snapshot Advanced Drainage Systems (WMS) has drawn fresh attention after a period of steady share moves, with the stock recently closing at $159.30 and posting positive returns over the past month and past 3 months. See our latest analysis for Advanced Drainage Systems. Beyond the recent share price move, Advanced Drainage Systems has built a clear upswing, with a 10.1% 30 day share price return alongside a 27.6% 1 year total shareholder return. This suggests momentum has...

If you are wondering whether TD SYNNEX at around US$150 is a fair deal or starting to look stretched, this article walks through what the current price might be implying about the company. The stock has been relatively steady in the near term, with a 0.3% decline over the last 7 days and a 0.7% gain over the last 30 days, while the 1 year return sits at 11.2% and the 3 and 5 year returns at 43.4% and 78.0% respectively. Recent coverage around TD SYNNEX has focused on its position as a large...

If you are looking at Centene and wondering whether the recent price is fair or not, this article walks through what the current share price might imply about the company's value. Centene's share price recently closed at US$45.75, with a 30 day return of 17.7% and a 1 year return showing a 26.5% decline, which may change how investors think about its risk and potential. Recent coverage around Centene has focused on its role as a major managed care player and how policy developments and...

Arbor Realty Trust announced that long-serving director Joseph Martello retired from its Board on December 31, 2025, and was replaced on January 5, 2026, by Mr. Natalone as a Class II director to fill the resulting vacancy. This Board transition comes as Arbor Realty Trust is working through elevated borrower delinquencies and challenging loan restructurings on its 2021–2022 vintage portfolio, adding governance change to an already complex operating backdrop. With the Board refresh occurring...

Why Willdan Group (WLDN) Is Back on Investors’ Radar Willdan Group (WLDN) has been in focus after completing its acquisition of Compass Municipal Advisors and winning a US$97 million energy savings performance contract with Alameda County, California, covering upgrades across 24 county sites. See our latest analysis for Willdan Group. Investors appear to be reacting to this mix of new contracts and an expanded municipal finance platform, with a 29.12% 1 month share price return and a very...

Garrett Motion recently received upbeat analyst coverage, including JPMorgan initiating an Overweight rating, while also announcing plans (on February 19, 2026) to release past fourth-quarter results and host an investor call on the same day. Analysts have highlighted fewer challenges for Garrett Motion’s internal combustion engine business alongside its push into zero-emission technologies, underscoring a dual-path technology approach that could reshape how investors view its long-term...

WaFd (WAFD) opened fiscal Q1 2026 with total revenue of US$187.9 million and basic EPS of US$0.79, while trailing twelve month revenue stood at US$734.5 million and EPS at US$2.89, giving investors a clear view of both the latest quarter and the broader earnings run rate. Over recent quarters, the bank has seen revenue move from US$171.1 million in Q1 2025 to US$187.9 million in Q1 2026, with quarterly EPS shifting from US$0.54 to US$0.79 across the same period, setting up this result against...

If you are wondering whether AppLovin’s share price still makes sense after a big run, or if the value case is starting to look stretched, this article is for you. The stock has pulled back recently, with a 12.2% decline over the last 7 days and a 13.4% decline over the last 30 days, although the 1 year return sits at 66.1% and the 3 year return is very large. Recent headlines have focused on AppLovin’s position in mobile app marketing and software, with attention on how its tools are being...

Amcor (AMCR) has just completed a 1 for 5 reverse stock split, with shares now trading on a split adjusted basis. This move directly affects how the packaging group’s stock appears in your portfolio. See our latest analysis for Amcor. The reverse split coincides with a softer patch for the stock, with a 1 day share price return of 7.29% decline and a 1 year total shareholder return of 10.64% decline, which points to fading momentum rather than a short term setback. If this corporate reset has...

Voyager Technologies (VOYG) is back on investor radars after securing a patent for manufacturing high purity optical crystals in space, and it is planning an International Space Station experiment in spring 2026 to validate the process. See our latest analysis for Voyager Technologies. The patent news has arrived alongside strong near term momentum, with a 1 month share price return of 53.96% and year to date share price return of 27.36% at a last close of $35.38. This suggests investors are...

Satellogic Inc. recently announced two key deals: supplying and in-orbit delivering two NewSat Mark V imaging satellites to Portugal’s CEiiA for the Atlantic Constellation, and securing a seven-figure contract to provide daily, high-frequency Earth observation coverage for a strategic customer. These agreements both expand European sovereign Earth observation capacity and underscore growing demand for persistent, high-resolution monitoring, supported by Satellogic’s vertically integrated,...

SkyWater Technology (SKYT) is back in focus after reporting quarterly revenue of US$150.74 million, up 60.7% year over year, with EPS of US$0.24 versus US$0.08 a year earlier. See our latest analysis for SkyWater Technology. The earnings beat and revenue jump have coincided with strong momentum, with a 30 day share price return of 123.05% and a 1 year total shareholder return of 186.58%, while the latest share price sits at US$33.10. If SkyWater’s recent move has caught your eye, it could be...

In early January 2026, Sarepta Therapeutics submitted a clinical trial application in New Zealand for INSIGHTT, the first-in-human study of SRP-1005, an siRNA candidate targeting Huntington’s disease, expanding its next-generation siRNA platform for neurodegenerative and pulmonary conditions. This move underscores Sarepta’s effort to balance the safety and regulatory setbacks around its gene therapy Elevidys with a broader, modality-diversified rare disease pipeline. We’ll now examine how...

If you are wondering whether Valero Energy is still reasonably priced after its recent run, this article will walk through what the current share price might imply about value. The stock recently closed at US$183.46, with a 1% decline over the last 7 days, a 12.6% gain over 30 days, 11.0% year to date, 34.2% over 1 year and a very large 5 year return. Recent news coverage has focused on Valero Energy within broader discussions about US refiners, fuel demand trends and energy sector...

Earlier this month, Enerpac Tool Group Corp. presented at CJS Securities’ 26th Annual “New Ideas for the New Year” Investor Conference on January 14, 2026, and has since attracted fresh analyst attention. William Blair’s initiation of coverage with a “Market Perform” rating adds another professional viewpoint to existing research, potentially broadening institutional interest and debate around Enerpac’s prospects. Next, we’ll examine how William Blair’s new coverage could influence Enerpac...

If you are wondering whether Halliburton is attractively priced or already reflects its prospects, this article will walk through what the current numbers suggest about the stock's value. Halliburton recently closed at US$32.57, with a return of 17.4% over the last 30 days, 10.0% year to date, 12.2% over the past year, a 14.3% decline over three years, and an 85.2% gain over five years. Recent news around Halliburton has largely focused on its role as a major oilfield services provider and...

A recent Montana court decision has pushed a PFAS class action further along, keeping Corteva (CTVA) in the spotlight as investors weigh potential legal exposure alongside the company’s broader agriculture and crop input business. See our latest analysis for Corteva. The recent PFAS ruling arrives after a period where Corteva’s share price has shown positive momentum, including a 13.42% 90 day share price return and a 12.89% 1 year total shareholder return. The Etlas biofuels joint venture...

If you are wondering whether Morgan Stanley shares still offer value after a strong run, this article walks through what the current price might be telling you. The stock last closed at US$189.09, with returns of 1.5% over 7 days, 8.2% over 30 days, 4.0% year to date, 41.0% over 1 year, 117.4% over 3 years and 199.2% over 5 years. Recent coverage around Morgan Stanley has focused on its role as a major global financial institution and on how market conditions influence investor appetite for...

Q4 2025 results put profitability in the spotlight Amdocs (DOX) has put investors on alert after Q4 2025 results showed a 9% year-over-year revenue decline alongside an 83% jump in operating income, which signals that management is focusing on margins rather than solely on top-line growth. See our latest analysis for Amdocs. At a share price of $83.77, Amdocs has a 1 month share price return of 5.09% and a 5 year total shareholder return of 31.29%, while the 3 year total shareholder return of...

If you are wondering whether Nutanix is attractively priced or just feels cheap after a rough patch, you are exactly who this breakdown is for. The stock recently closed at US$45.74, with returns of a 14.5% decline over 7 days, 8.9% decline over 30 days, 9.6% decline year to date, 29.8% decline over 1 year, but 70.7% and 36.5% gains over 3 and 5 years respectively. This points to mixed sentiment and changing expectations around the company. Recent attention on Nutanix has focused on its...

If you are wondering whether Chubb at around US$300 a share still offers solid value, starting with a clear look at what you are paying for each dollar of its business can help frame that question. The stock has recently slipped, with an estimated 2% decline over the last 7 days, 3.9% over the last 30 days and 3% year to date, while the 1 year return sits at 13.1% and the 3 and 5 year returns are about 42.5% and 113.0% respectively. These moves sit against a backdrop of ongoing interest in...

Primerica at a Glance After Recent Trading Moves With no single headline event driving attention today, interest in Primerica (PRI) is coming from its recent trading performance and the underlying financial profile that investors are reassessing. See our latest analysis for Primerica. Primerica’s recent share price return has been mixed, with a 2.7% gain over the last month and a modest 2.8% share price return year to date. However, the 1 year total shareholder return shows a 7.6% decline,...

Terns Pharmaceuticals (TERN) has been back in focus after the release of new Phase 1 data for its chronic myeloid leukemia candidate TERN-701, repeated conference exposure, and a large equity raise intended to fund pivotal trials. See our latest analysis for Terns Pharmaceuticals. At a recent share price of US$36.60, Terns has seen short term volatility, including a 1 day share price return of about 1% decline and a 1 month share price return of 12% decline. This is set against a very large 1...

Mirum Pharmaceuticals: recent performance snapshot Mirum Pharmaceuticals (MIRM) has attracted attention after a recent month where the share price return was 31.96%, following a 5.18% move over the past week and 23.83% over the past 3 months. Over the past year the stock posted a total return of 93.93%, while the year to date return stands at 16.63%. The shares last closed at US$91.05, with an intrinsic value estimate implying a 68.82% discount. See our latest analysis for Mirum...